We present two long-term survivors who underwent microwave coagulation therapy (MCT) for hepatocellular carcinoma (HCC). One patient was a 55-yr-old man having a solitary HCC of 25 mm in diameter associated with advanced liver cirrhosis. He underwent MCT instead of hepatic resection because he developed bleeding tendency during surgery. The other patient was a 78-yr-old woman having a 7 cm tumor in segment II and a 15 mm satellite lesion in segment IV. Because manipulation of the left hepatic lobe caused prolonged hypotension, only the main tumor was resected. The satellite lesion was treated with MCT. In both cases, tumors and surrounding liver parenchyma were widely coagulated. Postoperative courses were uneventful. The coagulated area shrank subsequently after surgery. Both patients are alive 39 and 55 months after MCT without tumor recurrence. This report proves that MCT is a curative treatment and an alternative to hepatic resection in selected patients with HCCs.

Download full-text PDF

Source

Publication Analysis

Top Keywords

long-term survivors
8
microwave coagulation
8
coagulation therapy
8
hepatocellular carcinoma
8
hepatic resection
8
satellite lesion
8
mct
5
survivors microwave
4
therapy hepatocellular
4
carcinoma case
4

Similar Publications

BACKGROUND: Patients with brain tumors continue to exhibit a lower quality of life than the general population, even after an extended period after surgery. Therefore, this study aimed to assess the postoperative quality of life of patients with brain tumors in South Korea and explore its determinants. METHODS: This study used a descriptive correlational design and collected data using questionnaires and electronic medical records.

View Article and Find Full Text PDF

Look-alike modelling in violence-related research: A missing data approach.

PLoS One

January 2025

Violence and Society Centre, City St George's, University of London, London, United Kingdom.

Violence has been analysed in silo due to difficulties in accessing data and concerns for the safety of those exposed. While there is some literature on violence and its associations using individual datasets, analyses using combined sources of data are very limited. Ideally data from the same individuals would enable linkage and a longitudinal understanding of experiences of violence and their (health) impacts and consequences.

View Article and Find Full Text PDF

TRAIL agonists rescue mice from radiation-induced lung, skin or esophageal injury.

J Clin Invest

January 2025

Laboratory of Translational Oncology and Translational Cancer Therapeutics, Warren Alpert Medical School of Brown University, Providence, United States of America.

Radiotherapy can be limited by pneumonitis which is impacted by innate immunity, including pathways regulated by TRAIL death receptor DR5. We investigated whether DR5 agonists could rescue mice from toxic effects of radiation and found two different agonists, parenteral PEGylated trimeric-TRAIL (TLY012) and oral TRAIL-Inducing Compound (TIC10/ONC201) could reduce pneumonitis, alveolar-wall thickness, and oxygen desaturation. Lung protection extended to late effects of radiation including less fibrosis at 22-weeks in TLY012-rescued survivors versus un-rescued surviving irradiated-mice.

View Article and Find Full Text PDF

Cancer survivors have an increased risk of developing Type 2 diabetes compared to the general population. Patients treated with cisplatin, a common chemotherapeutic agent, are more likely to develop metabolic syndrome and Type 2 diabetes than age- and sex-matched controls. Surprisingly, the impact of cisplatin on pancreatic islets has not been reported.

View Article and Find Full Text PDF

Purpose: Adolescent and young adult (AYA) malignant brain tumour (BT) survivors are at risk of adverse health outcomes, which may impact their health-related quality of life (HRQoL). This study aimed to investigate the (1) prevalence of physical and psychological adverse health outcomes, (2) the HRQoL, and (3) the association of adverse health outcomes and HRQoL among long-term AYA-BT survivors. Adverse health outcomes and HRQoL were compared to other AYA cancer (AYAC) survivors.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!